Journal article
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis
Multiple Sclerosis Journal, Vol.24(12), pp.1617-1626
2017
Abstract
Objective:
This propensity score–matched analysis from MSBase compared the effectiveness of cladribine with interferon β, fingolimod or natalizumab.
Methods:
We identified all patients with relapse-onset multiple sclerosis, exposure to the study therapies and ⩾1-year on-treatment follow-up from MSBase. Three pairwise propensity score–matched analyses compared treatment outcomes over 1 year. The outcomes were hazards of first relapse, disability accumulation and disability improvement events. Sensitivity analyses were completed.
Results:
The cohorts consisted of 37 (cladribine), 1940 (interferon), 1892 (fingolimod) and 1410 patients (natalizumab). The probability of experiencing a relapse on cladribine was lower than on interferon (p = 0.05), similar to fingolimod (p = 0.31) and higher than on natalizumab (p = 0.042). The probability of disability accumulation on cladribine was similar to interferon (p = 0.37) and fingolimod (p = 0.089) but greater than natalizumab (p = 0.021). The probability of disability improvement was higher on cladribine than interferon (p = 0.00017), fingolimod (p = 0.0025) or natalizumab (p = 0.00099). Sensitivity analyses largely confirmed the above results.
Conclusion:
Cladribine is an effective therapy for relapse-onset multiple sclerosis. Its effect on relapses is comparable to fingolimod and its effect on disability accrual is comparable to interferon β and fingolimod. Cladribine may potentially associate with superior recovery from disability relative to interferon, fingolimod and natalizumab.
Details
- Title
- Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis
- Authors/Creators
- T. Kalincik (Author/Creator)V. Jokubaitis (Author/Creator)T. Spelman (Author/Creator)D. Horakova (Author/Creator)E. Havrdova (Author/Creator)M. Trojano (Author/Creator)J. Lechner-Scott (Author/Creator)A. Lugaresi (Author/Creator)A. Prat (Author/Creator)M. Girard (Author/Creator)P. Duquette (Author/Creator)P. Grammond (Author/Creator)C. Solaro (Author/Creator)F. Grand’Maison (Author/Creator)R. Hupperts (Author/Creator)J. Prevost (Author/Creator)P. Sola (Author/Creator)D. Ferraro (Author/Creator)M. Terzi (Author/Creator)E. Butler (Author/Creator)M. Slee (Author/Creator)A. Kermode (Author/Creator)M. Fabis-Pedrini (Author/Creator)P. McCombe (Author/Creator)M. Barnett (Author/Creator)C. Shaw (Author/Creator)S. Hodgkinson (Author/Creator)H. Butzkueven (Author/Creator)
- Publication Details
- Multiple Sclerosis Journal, Vol.24(12), pp.1617-1626
- Publisher
- Sage Publications
- Identifiers
- 991005543772707891
- Copyright
- © 2018 SAGE Publications
- Murdoch Affiliation
- Institute for Immunology and Infectious Diseases
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
39 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.203 Neuromuscular Disorders
- 1.203.147 Multiple Sclerosis
- Web Of Science research areas
- Clinical Neurology
- Neurosciences
- ESI research areas
- Neuroscience & Behavior